scholarly journals Incidence and risk of celiac disease after type 1 diabetes: A population‐based cohort study using the health improvement network database

2018 ◽  
Vol 19 (8) ◽  
pp. 1422-1428 ◽  
Author(s):  
Mary Ellen Vajravelu ◽  
Ron Keren ◽  
David R. Weber ◽  
Ritu Verma ◽  
Diva D. De León ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Celiac Disease ◽  
Population Based ◽  
Health Improvement ◽  
Network Database ◽  
The Health Improvement Network

Incidence and Risk of Celiac Disease in Individuals with Type 1 Diabetes over the Lifespan—A Population-Based Cohort Study Using the Health Improvement Network Database

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1498-P
Author(s):  
MARY ELLEN VAJRAVELU ◽  
DIVA DE LEON ◽  
DAVID R. WEBER ◽  
RON KEREN ◽  
MICHELLE R. DENBURG ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Celiac Disease ◽  
Population Based ◽  
Health Improvement ◽  
Network Database ◽  
The Health Improvement Network

scholarly journals All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

2017 ◽  
Vol 102 (5) ◽  
pp. 1719-1725 ◽  
Author(s):  
Konstantinos A. Toulis ◽  
Brian H. Willis ◽  
Tom Marshall ◽  
Balachadran Kumarendran ◽  
Krishna Gokhale ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Low Risk ◽  
Health Improvement ◽  
Total Study Population ◽  
Risk Of Death ◽  
Network Database ◽  
All Cause Mortality ◽  
Risk Patients ◽  
The Health Improvement Network

Abstract Context: Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event. Objectives: To establish whether these benefits can be replicated in a real-world setting, should be expected with the use of dapagliflozin, and apply to T2DM patients at low risk of CVD. Design: General practice, population-based, retrospective cohort study (January 2013 to September 2015). Setting: The Health Improvement Network database. Participants: A total of 22,124 T2DM patients (4444 exposed to dapagliflozin; 17,680 unexposed T2DM patients) matched for age, sex, body mass index, T2DM duration, and smoking. Main Outcome Measures: The primary outcome was all-cause mortality (high and low risk for CVD) in the total study population, expressed as the adjusted incidence rate ratio (aIRR) with 95% confidence intervals (CIs). As a secondary analysis in the low-risk population, all-cause mortality and incident CVD were considered. Results: Patients with T2DM exposed to dapagliflozin were significantly less likely to die of any cause (aIRR: 0.50; 95% CI: 0.33 to 0.75; P = 0.001). Similarly, in low-risk patients, death from any cause was significantly lower in the cohort exposed to dapagliflozin (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.002). The difference in the risk of incident CVD did not reach statistical significance between groups in low-risk patients (aIRR: 0.89; 95% CI: 0.61 to 1.31; P = 0.546). Conclusions: Patients with T2DM who were exposed to dapagliflozin had a lower risk of death from any cause irrespective of baseline CVD status.

927-P: Risk of Substance Use Disorders among Adolescents and Emerging Adults with Type 1 Diabetes: A Population-Based Cohort Study

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 927-P
Author(s):  
ANA CREO ◽  
SWETHA SRIRAM ◽  
LISA VAUGHAN ◽  
AMY WEAVER ◽  
SEEMA KUMAR
Keyword(s):  
Substance Use ◽  
Type 1 Diabetes ◽  
Cohort Study ◽  
Emerging Adults ◽  
Substance Use Disorders ◽  
Population Based

scholarly journals Maternal and child gluten intake and risk of type 1 diabetes: The Norwegian Mother and Child Cohort Study

2019 ◽  
Author(s):  
Nicolai A Lund-Blix ◽  
German Tapia ◽  
Karl Mårild ◽  
Anne Lise Brantsaeter ◽  
Pål R Njølstad ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Confidence Interval ◽  
Population Based ◽  
Hazard Ratio ◽  
Adjusted Hazard Ratio ◽  
Pregnancy Cohort ◽  
Increased Risk ◽  
Mother And Child

ABSTRACTOBJECTIVETo examine the association between maternal and child gluten intake and risk of type 1 diabetes in children.DESIGNPregnancy cohortSETTINGPopulation-based, nation-wide study in NorwayPARTICIPANTS86,306 children in The Norwegian Mother and Child Cohort Study born from 1999 through 2009, followed to April 15, 2018.MAIN OUTCOME MEASURESClinical type 1 diabetes, ascertained in a nation-wide childhood diabetes registry. Hazard ratios were estimated using Cox regression for the exposures maternal gluten intake up to week 22 of pregnancy and child’s gluten intake when the child was 18 months old.RESULTSDuring a mean follow-up of 12.3 years (range 0.7-16.0), 346 children (0.4%) developed type 1 diabetes (incidence rate 32.6 per 100,000 person-years). The average gluten intake was 13.6 grams/day for mothers during pregnancy, and 8.8 grams/day for the child at 18 months of age. Maternal gluten intake in mid-pregnancy was not associated with the development of type 1 diabetes in the child (adjusted hazard ratio 1.02 (95% confidence interval 0.73 to 1.43) per 10 grams/day increase in gluten intake). However, the child’s gluten intake at 18 months of age was associated with an increased risk of later developing type 1 diabetes (adjusted hazard ratio 1.46 (95% confidence interval 1.06 to 2.01) per 10 grams/day increase in gluten intake).CONCLUSIONSThis study suggests that the child’s gluten intake at 18 months of age, and not the maternal intake during pregnancy, could increase the risk of type 1 diabetes in the child.WHAT IS ALREADY KNOWN ON THIS TOPICA national prospective cohort study from Denmark found that a high maternal gluten intake during pregnancy could increase the risk of type 1 diabetes in the offspring (adjusted hazard ratio 1.31 (95% confidence interval 1.001 to 1.72) per 10 grams/day increase in gluten intake). No studies have investigated the relation between the amount of gluten intake by both the mother during pregnancy and the child in early life and risk of developing type 1 diabetes in childhood.WHAT THIS STUDY ADDSIn this prospective population-based pregnancy cohort with 86,306 children of whom 346 developed type 1 diabetes we found that the child’s gluten intake at 18 months of age was associated with the risk of type 1 diabetes (adjusted hazard ratio 1.46 (95% confidence interval 1.06 to 2.01) per 10 grams/day increase in gluten intake). This study suggests that the child’s gluten intake at 18 months of age, and not the maternal intake during pregnancy, could increase the child’s risk of type 1 diabetes.

Type 1 Diabetes Mellitus and Risks of Major Psychiatric Disorders: A Nationwide Population-Based Cohort Study

2022 ◽  
pp. 101319
Author(s):  
Mu-Hong Chen ◽  
Shih-Jen Tsai ◽  
Ya-Mei Bai ◽  
Kai-Lin Huang ◽  
Tung-Ping Su ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Cohort Study ◽  
Type 1 Diabetes Mellitus ◽  
Psychiatric Disorders ◽  
Population Based
Sign in / Sign up

Export Citation Format

Share Document